{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:04:04Z","timestamp":1757617444689,"version":"3.44.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aimed to evaluate the prognostic significance of magnetic resonance imaging (MRI) parameters on biochemical failure-free survival (BFS) in patients diagnosed with intermediate-risk prostate cancer and treated with robotic ultrahypofractionated stereotactic body radiotherapy (SBRT) without androgen deprivation therapy (ADT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A\u00a0retrospective analysis was conducted in patients with intermediate-risk prostate cancer undergoing robotic SBRT delivered in five fractions with a\u00a0total radiation dose of 35\u201336.25\u202fGy. The primary endpoint was biochemical failure as defined by the Phoenix criteria. Among other clinicopathological data, T\u00a0stage,  Prostate Imaging-Reporting and Data System (PI-RADS) score, and multiparametric magnetic resonance imaging-based extra-prostatic extension (mEPE) score were collected and analyzed using the log-rank test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A\u00a0total of 74\u00a0patients were eligible for analysis. Median age at treatment was 68.8 years and median prostate volume was 47.8\u00a0cm<jats:sup>3<\/jats:sup>. Fifty-four and 14\u00a0patients were diagnosed with Gleason scores 7a and 7b, respectively. In total, 40\u00a0patients were classified as having unfavorable intermediate-risk prostate cancer according to  American Urological Association\/American Society for Radiation Oncology\/ Society of Urologic Oncology (AUA\/ASTRO\/SUO) guidelines. The median follow-up was 30\u00a0months (range: 4\u201391.2 months; interquartile range (IQR): 18.5\u201348\u00a0months). The 3\u2011year BFS was 92%. A\u00a0total of 12\u00a0(16.2%) biochemical failures were reported. In univariate analysis, an mEPE score of 5, the delivered total radiation dose (35\u202fGy vs. 36.25\u202fGy), and a\u00a0prostate-specific antigen (PSA) nadir &gt;1\u202fng\/ml were associated with lower BFS (mEPE\u2013BFS: <jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001, total radiation dose\u2013BFS: <jats:italic>p<\/jats:italic>\u202f=\u20090.04, PSA\u00a0nadir\u2013BFS: <jats:italic>p<\/jats:italic>\u202f=&lt;\u202f0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Patients diagnosed with intermediate-risk prostate cancer with a\u00a0high mEPE score are more likely to experience biochemical failure after SBRT. Treatment intensification measures, such as administration of concomitant ADT, should be considered.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00066-024-02355-y","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T13:57:40Z","timestamp":1736863060000},"page":"808-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic significance of the mEPE score in intermediate-risk prostate cancer patients undergoing ultrahypofractionated robotic SBRT"],"prefix":"10.1007","volume":"201","author":[{"given":"Lucas","family":"Mose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Isabel","family":"Loebelenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Althaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiwand","family":"Ahmadsei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Mathier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Broemel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena Carola","family":"Obmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6477-6655","authenticated-orcid":false,"given":"Mohamed","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"3","key":"2355_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung\u00a0H et\u00a0al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2355_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet\u00a0N et\u00a0al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part\u00a01: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243\u2013262","journal-title":"Eur Urol"},{"issue":"41","key":"2355_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel\u00a0DA et\u00a0al (2020) Prostate cancer incidence and survival, by stage and race\/ethnicity\u2014United States, 2001\u20132017. Mmwr Morb Mortal Wkly Rep 69(41):1473\u20131480","journal-title":"Mmwr Morb Mortal Wkly Rep"},{"issue":"3","key":"2355_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.euo.2020.03.002","volume":"3","author":"F Preisser","year":"2020","unstructured":"Preisser\u00a0F et\u00a0al (2020) Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol 3(3):270\u2013280","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"2355_CR5","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1007\/s00330-022-08595-9","volume":"32","author":"M Gatti","year":"2022","unstructured":"Gatti\u00a0M et\u00a0al (2022) MEPE-score: a\u00a0comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging. Eur Radiol 32(7):4942\u20134953","journal-title":"Eur Radiol"},{"issue":"2","key":"2355_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij\u00a0M et\u00a0al (2016) Accuracy of magnetic resonance imaging for local staging of prostate cancer: a\u00a0diagnostic meta-analysis. Eur Urol 70(2):233\u2013245","journal-title":"Eur Urol"},{"issue":"6","key":"2355_CR7","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.1996.14.6.1770","volume":"14","author":"AV D\u2019Amico","year":"1996","unstructured":"D\u2019Amico\u00a0AV et\u00a0al (1996) Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. JCO 14(6):1770\u20131777","journal-title":"JCO"},{"issue":"3","key":"2355_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1148\/radiol.210875","volume":"302","author":"AG Wibmer","year":"2022","unstructured":"Wibmer\u00a0AG et\u00a0al (2022) Local extent of prostate cancer at MRI versus prostatectomy histopathology: associations with long-term oncologic outcomes. Radiology 302(3):595\u2013602","journal-title":"Radiology"},{"issue":"8","key":"2355_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley\u00a0D et\u00a0al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5\u2011year outcomes of the randomised, non-inferiority, phase\u00a03 CHHiP trial. Lancet Oncol 17(8):1047\u20131060","journal-title":"Lancet Oncol"},{"key":"2355_CR10","doi-asserted-by":"crossref","unstructured":"Moore A et\u00a0al (2023) Long-term Outcomes from a\u00a0Phase\u00a01 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer. Eur Urol Oncol","DOI":"10.1016\/j.euo.2023.10.019"},{"issue":"17","key":"2355_CR11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy\u00a0FC et\u00a0al (2023) Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N\u00a0Engl J Med 388(17):1547\u20131558","journal-title":"N Engl J Med"},{"issue":"1","key":"2355_CR12","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell\u00a0R et\u00a0al (2012) Dose-Fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional Datasets: \u03b1\/\u03b2\u00a0= 1.4 (0.9\u20132.2) Gy. Int J Radiat Oncol Biol Phys 82(1):e17\u2013e24","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2355_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","volume":"52","author":"DJ Brenner","year":"2002","unstructured":"Brenner\u00a0DJ et\u00a0al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low \u03b1\/\u03b2 ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52(1):6\u201313","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2355_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/JU.0000000000000071","volume":"201","author":"SC Morgan","year":"2019","unstructured":"Morgan\u00a0SC et\u00a0al (2019) Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO and AUA evidence-based guideline. J\u00a0Urol 201(3):528\u2013534","journal-title":"J Urol"},{"issue":"3","key":"2355_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","volume":"110","author":"R van Dams","year":"2021","unstructured":"van Dams\u00a0R et\u00a0al (2021) Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients. Int J Radiat Oncol Biol Phys 110(3):731\u2013737","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2355_CR16","doi-asserted-by":"crossref","unstructured":"Foerster R et\u00a0al (2021) Stereotactic body radiotherapy for high-risk prostate cancer: a\u00a0systematic review. Cancers 13(4)","DOI":"10.3390\/cancers13040759"},{"issue":"3","key":"2355_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda\u00a0MG et\u00a0al (2018) Clinically localized prostate cancer: aUA\/ASTRO\/SUO guideline. Part I:\u00a0risk stratification, shared decision making, and care options. J\u00a0Urol 199(3):683\u2013690","journal-title":"J Urol"},{"issue":"10","key":"2355_CR18","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","volume":"30","author":"M de Rooij","year":"2020","unstructured":"de Rooij\u00a0M et\u00a0al (2020) ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training. Eur Radiol 30(10):5404\u20135416","journal-title":"Eur Radiol"},{"issue":"6","key":"2355_CR19","first-page":"298","volume":"41","author":"NJV As","year":"2023","unstructured":"As\u00a0NJV et\u00a0al (2023) PACE-A: An international phase\u00a03 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)\u2014Primary endpoint analysis. JCO 41(6):298\u2013298","journal-title":"JCO"},{"issue":"11","key":"2355_CR20","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand\u00a0DH et\u00a0al (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase\u00a03, non-inferiority trial. Lancet Oncol 20(11):1531\u20131543","journal-title":"Lancet Oncol"},{"key":"2355_CR21","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der C et\u00a0al (2023) Five Fractions versus Seven Fractions SBRT for Intermediate- and High-Risk Prostate Cancer: A\u00a0Propensity Score Matched Pair Analysis. Cancers 15(24)","DOI":"10.3390\/cancers15245815"},{"issue":"9","key":"2355_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00345-018-2295-6","volume":"36","author":"BHE Jansen","year":"2018","unstructured":"Jansen\u00a0BHE et\u00a0al (2018) Local staging with multiparametric MRI in daily clinical practice: diagnostic accuracy and evaluation of a\u00a0radiologic learning curve. World J Urol 36(9):1409\u20131415","journal-title":"World J Urol"},{"key":"2355_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.urology.2019.04.023","volume":"130","author":"C Draulans","year":"2019","unstructured":"Draulans\u00a0C et\u00a0al (2019) Impact of magnetic resonance imaging on prostate cancer staging and European association of urology risk classification. Urology 130:113\u2013119","journal-title":"Urology"},{"issue":"3","key":"2355_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.prro.2017.11.008","volume":"8","author":"A Gonzalez-Motta","year":"2018","unstructured":"Gonzalez-Motta\u00a0A, Roach\u00a0M (2018) Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: where are we now? Pract Radiat Oncol 8(3):185\u2013202","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"2355_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.euo.2020.08.008","volume":"5","author":"TFW Soeterik","year":"2022","unstructured":"Soeterik\u00a0TFW et\u00a0al (2022) Development and external validation of a\u00a0novel nomogram to predict side-specific extraprostatic extension in patients with prostate cancer undergoing radical prostatectomy. Eur Urol Oncol 5(3):328\u2013337","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"2355_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13244-023-01486-7","volume":"14","author":"M Zhu","year":"2023","unstructured":"Zhu\u00a0M et\u00a0al (2023) Diagnostic performance of prediction models for extraprostatic extension in prostate cancer: a\u00a0systematic review and meta-analysis. Insights Imaging 14(1):140","journal-title":"Insights Imaging"},{"issue":"2","key":"2355_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.clgc.2023.11.010","volume":"22","author":"MW Ma","year":"2024","unstructured":"Ma\u00a0MW et\u00a0al (2024) Integration of multiparameter MRI into conventional pretreatment risk factors to predict positive surgical margins after radical prostatectomy. Clin Genitourin Cancer 22(2):281\u2013290.e1","journal-title":"Clin Genitourin Cancer"},{"issue":"15","key":"2355_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N v. As","year":"2024","unstructured":"v. As\u00a0N et\u00a0al (2024) Phase\u00a03 trial of stereotactic body radiotherapy in localized prostate cancer. N\u00a0Engl J Med 391(15):1413\u20131425","journal-title":"N Engl J Med"},{"key":"2355_CR29","doi-asserted-by":"crossref","unstructured":"Katz AJ, Kang J (2014) Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a\u00a07-year study. Front Oncol 4:","DOI":"10.3389\/fonc.2014.00240"},{"key":"2355_CR30","doi-asserted-by":"crossref","unstructured":"Yasar B et\u00a0al (2024) Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: primary outcomes of the SPARC phase\u00a02 trial. Int J Radiat Oncol Biol Phys","DOI":"10.1016\/j.ijrobp.2024.03.009"},{"issue":"7","key":"2355_CR31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer\u00a0LGW et\u00a0al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase\u00a0III trial. J\u00a0Clin Oncol 39(7):787\u2013796","journal-title":"J Clin Oncol"},{"issue":"3","key":"2355_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","volume":"53","author":"N Cellini","year":"2002","unstructured":"Cellini\u00a0N et\u00a0al (2002) Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53(3):595\u2013599","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2355_CR33","doi-asserted-by":"publisher","first-page":"109503","DOI":"10.1016\/j.radonc.2023.109503","volume":"181","author":"WL Ong","year":"2023","unstructured":"Ong\u00a0WL et\u00a0al (2023) Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion\u2014Results from the 2SMART phase\u00a02\u00a0trial. Radiother Oncol 181:109503","journal-title":"Radiother Oncol"},{"issue":"10","key":"2355_CR34","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s00066-022-01968-5","volume":"198","author":"E Mathier","year":"2022","unstructured":"Mathier\u00a0E, Heusel\u00a0A, Shelan\u00a0M (2022) Multimodale Therapieans\u00e4tze beim Hochrisikoprostatakarzinom \u2013 was wann? Strahlenther Onkol 198(10):962\u2013965","journal-title":"Strahlenther Onkol"},{"key":"2355_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","volume":"59","author":"R Hannan","year":"2016","unstructured":"Hannan\u00a0R et\u00a0al (2016) Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a\u00a0multi-institutional clinical trial. Eur J Cancer 59:142\u2013151","journal-title":"Eur J Cancer"},{"issue":"3","key":"2355_CR36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ijrobp.2021.04.013","volume":"111","author":"A Nabid","year":"2021","unstructured":"Nabid\u00a0A et\u00a0al (2021) Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a\u00a0Randomized Phase\u00a03 Trial. Int J Radiat Oncol Biol Phys 111(3):732\u2013740","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2355_CR37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","volume":"98","author":"CAF Lawton","year":"2017","unstructured":"Lawton\u00a0CAF et\u00a0al (2017) Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202. Int J Radiat Oncol Biol Phys 98(2):296\u2013303","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"2355_CR38","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla\u00a0M et\u00a0al (2009) Duration of androgen suppression in the treatment of prostate cancer. N\u00a0Engl J Med 360(24):2516\u20132527","journal-title":"N Engl J Med"},{"issue":"4","key":"2355_CR39","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","volume":"74","author":"A Nabid","year":"2018","unstructured":"Nabid\u00a0A et\u00a0al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a\u00a0randomized phase\u00a0III trial. Eur Urol 74(4):432\u2013441","journal-title":"Eur Urol"},{"issue":"1","key":"2355_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","volume":"127","author":"C Salembier","year":"2018","unstructured":"Salembier\u00a0C et\u00a0al (2018) ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol 127(1):49\u201361","journal-title":"Radiother Oncol"},{"issue":"10","key":"2355_CR41","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/pros.24350","volume":"82","author":"RS Flammia","year":"2022","unstructured":"Flammia\u00a0RS et\u00a0al (2022) Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients. Prostate 82(10):1051\u20131059","journal-title":"Prostate"},{"issue":"2","key":"2355_CR42","doi-asserted-by":"publisher","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","volume":"2","author":"AU Kishan","year":"2019","unstructured":"Kishan\u00a0AU et\u00a0al (2019) Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open 2(2):e188006","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2355_CR43","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen\u00a0PL et\u00a0al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67(5):825\u2013836","journal-title":"Eur Urol"},{"issue":"3","key":"2355_CR44","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ijrobp.2019.06.2539","volume":"105","author":"NY Jiang","year":"2019","unstructured":"Jiang\u00a0NY et\u00a0al (2019) Multi-institutional analysis of prostate-specific antigen kinetics after Stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 105(3):628\u2013636","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2355_CR45","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3389\/fonc.2020.00936","volume":"10","author":"DB Fuller","year":"2020","unstructured":"Fuller\u00a0DB et\u00a0al (2020) Prostate SBRT: comparison the efficacy and toxicity of two different dose fractionation schedules. Front Oncol 10:936","journal-title":"Front Oncol"},{"issue":"9","key":"2355_CR46","first-page":"e1668","volume":"9","author":"A Katz","year":"2017","unstructured":"Katz\u00a0A (2017) Stereotactic body radiotherapy for low-risk prostate cancer: a\u00a0ten-year analysis. Cureus 9(9):e1668","journal-title":"Cureus"},{"issue":"4","key":"2355_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.prro.2015.11.002","volume":"6","author":"AU Kishan","year":"2016","unstructured":"Kishan\u00a0AU et\u00a0al (2016) SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Pract Radiat Oncol 6(4):268\u2013275","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2355_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1748-717X-8-118","volume":"8","author":"AJ Katz","year":"2013","unstructured":"Katz\u00a0AJ et\u00a0al (2013) Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6\u00a0years. Radiat Oncol 8(1):118","journal-title":"Radiat Oncol"},{"issue":"2","key":"2355_CR49","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","volume":"102","author":"RM Meier","year":"2018","unstructured":"Meier\u00a0RM et\u00a0al (2018) Multicenter trial of Stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys 102(2):296\u2013303","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10196","key":"2355_CR50","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark\u00a0A et\u00a0al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5\u2011year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase\u00a03\u00a0trial. Lancet 394(10196):385\u2013395","journal-title":"Lancet"},{"issue":"2","key":"2355_CR51","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00259-023-06438-3","volume":"51","author":"S Adebahr","year":"2024","unstructured":"Adebahr\u00a0S et\u00a0al (2024) The prognostic significance of a\u00a0negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imaging 51(2):558\u2013567","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2355_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.semnuclmed.2023.07.002","volume":"54","author":"H Duan","year":"2024","unstructured":"Duan\u00a0H, Iagaru\u00a0A (2024) PSMA PET for Detection of Recurrence. Semin Nucl Med 54(1):77\u201386","journal-title":"Semin Nucl Med"},{"issue":"6","key":"2355_CR53","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1007\/s00330-023-10427-3","volume":"34","author":"A Ponsiglione","year":"2024","unstructured":"Ponsiglione\u00a0A et\u00a0al (2024) Radiomics for the identification of extraprostatic extension with prostate MRI: a\u00a0systematic review and meta-analysis. Eur Radiol 34(6):3981\u20133991","journal-title":"Eur Radiol"},{"issue":"3","key":"2355_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.semradonc.2023.03.003","volume":"33","author":"RB Ger","year":"2023","unstructured":"Ger\u00a0RB et\u00a0al (2023) The promise and future of radiomics for personalized radiotherapy dosing and adaptation. Semin Radiat Oncol 33(3):252\u2013261","journal-title":"Semin Radiat Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02355-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:23:14Z","timestamp":1757136194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02355-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2355"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02355-y","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.\u00a0Mose, L.I.\u00a0Loebelenz, A.\u00a0Althaus, M.\u00a0Ahmadsei, E.\u00a0Mathier, I.\u00a0Broemel, D.M.\u00a0Aebersold, V.C.\u00a0Obmann, and M.\u00a0Shelan declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. We have obtained regional ethics committee approval (BE 2022-00120) that our study has been performed according to the ethical standards. A general informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}